Who are rhGH injection's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Skytrofa, MACIMORELIN ACETATE, Macrilen, Egrifta, Trovert, Trovert.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/rhgh-injection.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

rhGH injection — Competitive Intelligence Brief

rhGH injection (rhGH injection) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Growth hormone. Area: Endocrinology.

marketed Growth hormone Growth hormone receptor (GHR) Endocrinology Small molecule Live · refreshed every 30 min

Target snapshot

rhGH injection (rhGH injection) — Changchun GeneScience Pharmaceutical Co., Ltd.. Recombinant human growth hormone (rhGH) binds to growth hormone receptors to stimulate growth, metabolism, and protein synthesis.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
rhGH injection TARGET	rhGH injection	Changchun GeneScience Pharmaceutical Co., Ltd.	marketed	Growth hormone	Growth hormone receptor (GHR)
Skytrofa	LONAPEGSOMATROPIN	Ascendis Pharma Encocrinology Div A/S	marketed	Recombinant Human Growth Hormone [EPC]	Growth hormone receptor	2021-01-01
MACIMORELIN ACETATE	MACIMORELIN ACETATE		marketed	Growth Hormone Secretagogue Receptor Agonist [EPC]		2017-01-01
Macrilen	MACIMORELIN	Aeterna Zentaris	marketed	Growth Hormone Secretagogue Receptor Agonist	Growth hormone secretagogue receptor type 1	2017-01-01
Egrifta	TESAMORELIN ACETATE	Theratechnologies	marketed	Growth Hormone Releasing Factor Analog	Growth hormone-releasing hormone receptor	2010-01-01
Trovert	PEGVISOMANT	Pfizer	marketed	Growth Hormone Receptor Antagonist	Growth hormone receptor	2003-01-01
Trovert	somavert	Pfizer	marketed	Growth Hormone Receptor Antagonist	Growth hormone receptor	2003-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Growth hormone class)

Assistance Publique - Hôpitaux de Paris · 2 drugs in this class
Changchun GeneScience Pharmaceutical Co., Ltd. · 1 drug in this class
Granata Bio Corporation · 1 drug in this class
Merck KGaA, Darmstadt, Germany · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). rhGH injection — Competitive Intelligence Brief. https://druglandscape.com/ci/rhgh-injection. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab